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Bortezomib is an inhibitor of 26S proteasome, which is an effective treatment for 
multiple myeloma. The common adverse effects of bortezomib are asthenic condi-
tions, gastrointestinal disturbances, and peripheral neuropathy. Here we describe a 
patient with dyspnea and general weakness because of complete atrioventricular 
block while receiving bortezomib. We immediately stopped bortezomib, and after 
inserting a permanent VDD pacemaker, the patients’ symptoms disappeared. 
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INTRODUCTION    
Multiple myeloma is a hematologic malignancy characterized by the proliferation 
of monoclonal plasma cells that produce monoclonal immunoglobulins. Treat-
ments for multiple myeloma have significantly changed with improved under-
standing of potential myeloma targets, and have led to the development of molecu-
lar-targeted antineoplastic agents, such as bortezomib. Bortezomib is an inhibitor 
of 26S proteasome, which is effective treatment in multiple myeloma. This inhibi-
tion makes the accumulation of poly-ubiquitinated proteins involved in a multi-
tude of signaling pathways. Apoptosis is one of the resulting effects, with relative 
selectivity for malignant cells as opposed to normal cells.1 
The common adverse effects of bortezomib are asthenic conditions, gastrointes-
tinal disturbances, and peripheral neuropathy.2 Cardiac rhythm abnormalities sec-
ondary to use of bortezomib is uncommon. In this report we describe a multiple 
myeloma patient who experienced a complete atrioventricular (AV) block while 
receiving bortezomib with dexamethasone. 
CASE REPORT
A-65-year-old female with no prior cardiovascular history was admitted to the 
hospital complaining of a sudden onset of weakness and dyspnea. There was no 
chest pain or palpitation. Her pulse was found to be 53 beats per minute (bpm) and Complete AV Block Secondary to Bortezomib Use
Yonsei Med J   http://www.eymj.org   Volume 52   Number 1   January 2011 197
ments with normal ventricular systolic function, ejection 
fraction revealing 65%. A myocardial biopsy was done to 
distinguish from amyloidosis but revealed no evidence. 
The past medical history showed a stage IIA multiple 
myeloma IgG kappa diagnosed 6 months prior. At diagno-
sis she had an M-protein of 4.38 g/dL, hemoglobin 9.7 g/dL 
normocytic anemia and creatinine 0.8 mg/dL, with normal 
renal function. Her bone marrow aspiration and biopsy re-
vealed 52% of plasma cells. There was neither hypercalce-
mia nor neuropathy but the patient had a general ache with 
multiple compression fractures at the spine.
In first line chemotherapy, a regimen of peroral (PO) 
melphalan 0.15 mg/kg with prednisolone on days 1-7 every 
four weeks was started. After 3 cycles of melphalan and 
prednisolone the patient’s M-protein decreased by 4.00 g/dL. 
But she still complained of a general ache and her total pro-
teins were still high. Considering this to be a stable disease 
state we changed the chemotherapy regimen to IV bortezo-
mib 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks and 
dexamethasone 40 mg PO weekly. The response was good, 
with decrease of M-protein to 0.66 g/dL and disappearance 
of general ache after 2nd cycle of bortezomib. When her 
acute symptomatic bradycardia appeared, she was expected 
her blood pressure was 110/70 mmHg. The physical exami-
nation revealed a split second heart sound with no other ab-
normalities. The chest X-ray was normal with slight cardio-
megaly (Fig. 1). The laboratory tests showed normal kidney 
and liver function, cardiac enzyme and electrolytes, with 
normocytic anemia of Hb 9.5 g/dL. The electrocardiogram 
revealed a complete AV block with premature ventricular 
block and ventricular rate of 53 bpm (Fig. 2B). Previous 
electrocardiograms had revealed no conduction abnormali-
ties (Fig. 2A). Holter monitoring also showed complete AV 
block. The echocardiogram showed both atrial enlarge-
Fig. 1. Chest X-ray at admission. The chest X-ray is normal with a slight car-
diomegaly. 
Fig. 2. (A) A 12-lead electrocardiogram of the patient before using bortezomib. No specific ST or T abnormalities, with normal sinus 
rhythm. (B) A 12-lead electrocardiogram of the patient at admission. More P waves than the QRS complexes and dissociation with P 
waves and QRS complexes, which stands for complete atrioventricular block.
A B
Fig. 3. (A) Chest X-ray after pacemaker insertion. The pacemaker lead is shown at the apex of right ventricle in the X-ray (arrow), which 
indicates successful pacemaker insertion. (B) A 12-lead electrocardiogram after insertion of pacemaker. The electrocardiogram shows 
successful pacing of the pacemaker.
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erally thought to be rare, moderate shortness of breath, pal-
pitations and pedal edema have been documented in pa-
tients treated with this agent,6 which demonstrates the 
possibility that bortezomib could also damage the conduc-
tion system of the heart. 
In conclusion, cardiac rhythm abnormalities, including 
complete AV block are rare side effects of bortezomib use, 
but can be critical to the patient. Thus, early recognition of 
this side effect and prompt withdrawal of bortezomib is 
needed to prevent fatal outcomes. 
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to have a 3rd cycle of bortezomib. 
A permanent VDD pacemaker was successfully inserted 
(Fig. 3), and the symptoms of dyspnea and general weak-
ness completely disappeared. Because bortezomib was 
thought to be the reason for the AV block, it was immedi-
ately stopped and the regimen was changed to thalidomide, 
cyclophosimide, and dexamethasone regimen.
DISCUSSION
Cases of cardiac arrhythmias and conduction disorders 
caused by bortezomib were observed in several clinical tri-
als.3-5 Early studies exploring the safety of prolonged thera-
py with bortezomib in a relapsed/refractory myeloma set-
ting, Berenson, et al.5 reported a case of complete AV block, 
and only one case was reported by Dasanu1 to insert per-
mant pacemaker because of a complete AV block second-
ary to bortezomib use.1 In our patient’s case, it is possible 
that the multiple myeloma itself combined with bortezomib 
impaired AV conduction in a patient with an underlying AV 
node problem. But since the patient had neither a pre-exist-
ing heart condition nor any type of arrhythmia before re-
ceiving bortezomib, we believe that botezomib played a 
large part occurring complete AV block.
The mechanism of a complete AV block secondary to 
bortezomib is uncertain. Bortezomib is a dipeptide boro-
nate proteasome inhibitor, which reversibly inhibits the 26S 
proteasome. But it is postulated that bortezomib affects not 
only nuclear factor- kB activity but also various signaling 
pathways its metabolites might cause cellular damage of 
the heart. Although cardiac toxicity with bortezomib is gen-